HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

(S)- 1- (5- hydroxy- 1,5- dimethylhexyl)- 3- (7- (4- methoxyphenyl)- (1,2,4- triazolo(1,5- a)pyrimidin- 2- yl))urea

structure in first source

Also Known As:

NK026680

Networked: 1 relevant articles (1 outcomes, 1 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- 1-Ring Heterocyclic Compounds
  - Azoles: 2138
    - Triazoles: 1533
      - (S)-1-(5-hydroxy-1,5-dimethylhexyl)-3-(7-(4-methoxyphenyl)-(1,2,4-triazolo(1,5-a)pyrimidin-2-yl))urea: 1
  - Pyrimidines: 510
    - (S)-1-(5-hydroxy-1,5-dimethylhexyl)-3-(7-(4-methoxyphenyl)-(1,2,4-triazolo(1,5-a)pyrimidin-2-yl))urea: 1

Experts

1.	Abe, Fuminori: 1 article (11/2006)
2.	Furukawa, Hiroshi: 1 article (11/2006)
3.	Ichimura, Eiji: 1 article (11/2006)
4.	Nose, Masato: 1 article (11/2006)
5.	Ono, Masao: 1 article (11/2006)
6.	Saiga, Kan: 1 article (11/2006)
7.	Tokunaka, Kazuhiro: 1 article (11/2006)
8.	Toyoda, Eriko: 1 article (11/2006)
9.	Yoshida, Minako: 1 article (11/2006)

Related Diseases

1.	Lymphadenopathy 11/01/2006 - "The newly identified DC inhibitor, NK026680, prevented the onset of RPGN, autoantibody production, and lymphadenopathy in SCG/Kj mice, suggesting a crucial role for DC function in these autoimmune phenotypes. " 11/01/2006 - "The efficacy of NK026680 was evaluated using the mortality of mice, the results of urinalysis, histopathologic evaluation for glomerular injury, and immunofluorescence staining for the detection of immune complex (IC) deposition in glomeruli, and by assessing lymphadenopathy and measuring autoantibody titers. " 11/01/2006 - "Oral administration of NK026680 at a dosage of 25 mg/kg once daily or 50 mg/kg once daily significantly suppressed 1) spontaneous mortality, 2) proteinuria and hematuria, 3) blood urea nitrogen levels, 4) glomerular damage characterized histopathologically, 5) IC deposition in glomeruli, 6) the development of pANCA and anti-DNA antibodies, and 7) lymphadenopathy. "
2.	Glomerulonephritis 11/01/2006 - "This study was undertaken to evaluate NK026680 suppression of DC functions in preventing development of rapidly progressive glomerulonephritis (RPGN) and perinuclear antineutrophil cytoplasmic antibodies (pANCA) in SCG/Kj mice. " 11/01/2006 - "NK026680, a novel suppressant of dendritic cell function, prevents the development of rapidly progressive glomerulonephritis and perinuclear antineutrophil cytoplasmic antibody in SCG/Kj mice."
3.	Proteinuria 11/01/2006 - "Oral administration of NK026680 at a dosage of 25 mg/kg once daily or 50 mg/kg once daily significantly suppressed 1) spontaneous mortality, 2) proteinuria and hematuria, 3) blood urea nitrogen levels, 4) glomerular damage characterized histopathologically, 5) IC deposition in glomeruli, 6) the development of pANCA and anti-DNA antibodies, and 7) lymphadenopathy. "
4.	Hematuria 11/01/2006 - "Oral administration of NK026680 at a dosage of 25 mg/kg once daily or 50 mg/kg once daily significantly suppressed 1) spontaneous mortality, 2) proteinuria and hematuria, 3) blood urea nitrogen levels, 4) glomerular damage characterized histopathologically, 5) IC deposition in glomeruli, 6) the development of pANCA and anti-DNA antibodies, and 7) lymphadenopathy. "
5.	Graft vs Host Disease (Graft-Versus-Host Disease) 11/01/2006 - "NK026680 is a newly identified type of immunosuppressive agent that inhibits dendritic cell (DC) functions and consequently reduces the mortality of mice with experimental acute graft-versus-host disease. "

Related Drugs and Biologics

1.	Autoantibodies
2.	Antigen-Antibody Complex (Immune Complex)
3.	Antineutrophil Cytoplasmic Antibodies (ANCA)
4.	Urea (Carbamide)
5.	Nitrogen
6.	Immunosuppressive Agents (Immunosuppressants)
7.	Antinuclear Antibodies

Related Therapies and Procedures

1.	Oral Administration